- Home
- CVR vs CANF Comparison
CVR vs CANF Comparison
Compare CVR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- CANF
- Stock Information
- Founded
- CVR 1920
- CANF 1994
- Country
- CVR United States
- CANF Israel
- Employees
- CVR N/A
- CANF N/A
- Industry
- CVR Industrial Machinery/Components
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CVR Industrials
- CANF Health Care
- Exchange
- CVR Nasdaq
- CANF Nasdaq
- Market Cap
- CVR 9.5M
- CANF 9.6M
- IPO Year
- CVR N/A
- CANF N/A
- Fundamental
- Price
- CVR $9.40
- CANF $0.41
- Analyst Decision
- CVR
- CANF Strong Buy
- Analyst Count
- CVR 0
- CANF 2
- Target Price
- CVR N/A
- CANF $14.50
- AVG Volume (30 Days)
- CVR 2.2K
- CANF 274.5K
- Earning Date
- CVR 11-11-2025
- CANF 11-27-2025
- Dividend Yield
- CVR 1.33%
- CANF N/A
- EPS Growth
- CVR N/A
- CANF N/A
- EPS
- CVR N/A
- CANF N/A
- Revenue
- CVR $25,617,681.00
- CANF $560,000.00
- Revenue This Year
- CVR N/A
- CANF $461.72
- Revenue Next Year
- CVR N/A
- CANF N/A
- P/E Ratio
- CVR N/A
- CANF N/A
- Revenue Growth
- CVR N/A
- CANF N/A
- 52 Week Low
- CVR $8.15
- CANF $0.41
- 52 Week High
- CVR $22.27
- CANF $2.50
- Technical
- Relative Strength Index (RSI)
- CVR 40.86
- CANF 23.12
- Support Level
- CVR $9.40
- CANF $0.46
- Resistance Level
- CVR $9.75
- CANF $0.49
- Average True Range (ATR)
- CVR 0.23
- CANF 0.03
- MACD
- CVR -0.00
- CANF -0.00
- Stochastic Oscillator
- CVR 35.85
- CANF 5.67
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).